896
KLINICKÁ341804301074588109168189242288347
FARMAKOLOGIE708804301074392139212266313373416475534555599
A13288043010753
FARMACIE1402804301074292139211266317337381
/18048043010757
Klin1880804301077091109157
Farmakol2057804301074279105179220258305325
Farm2402804301074178105179
2021;2601804301074486128167177
35(3):2798804301074485107149170185
56–603003804301074487135182227
/32508043010757
www.klinickafarmakologie.cz4568804301076513320121425327329234035839843647950254457164568672477179183988990895196610061045
601828026012657116
HLAVNÍ341207012670127198263336370
TÉMA732207012658115205275
Léčba3413650106296196132172
pacientů52836501063370104121153194226268
přípravkem8113650106336986121156198233269301356
buněčné118236501063475117148183225256
terapie14533650106316399141175192224
axikabtagen16923650106397794129171207238275313344386
ciloleucel20933650106335182121152184225260292323
Literatura34354601265383123179221277317379421476
1.3437000853648
Friedberg40570108330496599139177213234271
JW.692701083217989
Relapsed/refractory796701083336783115154180215254280299333352374407439462499520554
diffuse136570108336517089127153188
large1568701083134465103138
B‑cell1721701083335689122138153
lym‑18897010831244102124
phoma.3438010833977115174206219
Hematology5788010834782140172194231247285325357
Am95080108344102
Soc10688010833574106
Hematol11908010834782140172194231247
Educ14528010833674112144
Program1611801083395997136157190248
2011;18758010833771103131139
2011(1):3439010833468100128143174189201
498–505.5599010833467102139173207241253
2.34310000853550
Crump4071001083365794150188
M,61010010835063
Neelapu68810010834175109124155193230
SS,9331001083296072
Farooq10201001083295778114151190
U1225100108340
et127910010833152
al.13461001083294355
Outcomes141610010834381102132168225259285
in171510010831249
refracto‑1778100108318516990122153177212235
ry34311010832155
diffuse413110108343587897136162197
large6261101083195273111146
B‑cell7871101083416497131147162
lymphoma:96411010832052111150188227285318330
results13091101083266087124139162190
from15141101083234683141
the167011010832765100
interna‑17861101083195779113134173205228
tional3431201083223775113146161
SCHOLAR-151912010833373118166198241277299330
study.8641201083264987126158168
Blood10481201083355189128167
2017;123012010833569100130140
130(16):13851201083346499118150181199211
1800–1808.161112010833465101137175206237272308321
3.34313000853651
Polgárová4091301083417894134167188226258291
K,71613010834055
Trněný7871301083385595130168199
M.100213010836074
Imunoterapie109213010832078116155194216250272305345360396
v1503130108337
léčbě15561301083205588128164
lymfomů.173513010832052112131169228266278
Postgraduální3431401083357299122160181214253290323338376391
medicína74914010835793132147179194232265
2020;102914010833468101135148
22(1):11921401083346987118133145
9–18.135214010833472102133147
4.34315000853651
Agresivní40915010834785106141168182215254269
lymfomy.69415010832052111130167226257267
In:9761501083205871
Belada10621501083417692124163196
D,127315010835162
Trněný13501501083385594129167198
M1563150108360
(editoři).16391501083235696111134171193208227238
Dia‑18931501083506698120
gnostické34316010833876115142165180212242277
a635160108337
léčebné6871601083205588122161200235
postupy93716010834483110133171210242
u1194160108343
nemocných125216010834378136174207246276308346
s1613160108332
lymfomy,166016010832052111130168226257267
XI.19421601083435972
vydání.34317010833266104137175190202
KAP56117010833579115
CZ69117010834079
Brno7861701083355695133
2020:93517010833468101135148
97–102.109817010833467100130162195207
5.34318000853650
Ross40818010833674101128
J,55118010832436
Carver6031801083407394129163184
ML.80218010835587101
MediaKite91818010835590130145177212229251285
announces121818010833270108147185223255289315
Yescarta®15491801083356693125158179204237264
CAR182818010834083119
T­196218010833351
‑cell3431901083215588104119
therapy4771901083205893114147186217
improved71019010831270109131168200234274
event‑free9991901083326498136158178197219253289
survival13031901083246182117133165198214
by153219010833668
60%161519010833267120
over175119010833567101122
che‑188919010832967102125
motherapy34320010835795117155190211244283314
plus6722001083365290116
stem8032001083244780138
cell956200108329637893
transplant10642001083194174112138177192224262284
in136320010831250
second‑line14282001083245991128166205227244258296331
relapsed17742001083185268100139166200240
or34321010833759
refractory417210108320547395128160185222243277
large7092101083144768106141
B‑cell8652101083355891125141156
lymphoma103621010831446104144182220279311
[online].13622101083185493108123161196213225
2021160221010833368100132
[cit.174921010831848638699
202110-11].1863210108334681001323432201083346691122150166178
Dostupné53622010835190117141179219258293
z:84522010833348
https://www.businesswire.com/news/90822010834365901301571691972172693233773884284674945095475836106376897057267617738068439029289651001105210801106
home/20210628005449/en/34323010833876134169195230264297329360396429463498534568604641674697729767793
6.34324000853652
Lee40924010833165100
DW,525240108344102111
Santomasso65224010833164102124161219251278304343
BD,10102401083348091
Locke111724010833068100130164
FL129724010833162
et137524010833355
al.14452401083314659
ASTCT152024010834074108147183
consensus171824010833167106132167205232269295
grading3432501083385992131146184223
for5822501083165375
cytokine6722501083296388125155172210245
release9322501083185268103135161196
syndrome11442501083235695134155192251286
and144525010833068107
neurologic156725010833570108129166182220260275307
toxi‑18892501083205787103125
city3432601083314669103
associated4612601083376390128161176208230263303
with7792601083567294132
immune92726010831977135172211246
effector11882601083395877112145169206227
cells.14312601083367085100126140
Biol15862601083415694110
Blood17112601083415694133173
Ma‑189926010836092115
rrow3432701083214280131
Transplant4892701083335083121147186202234272294
2019;79827010833468100130143
25:9562701083356980
625–638.105227010833467102138176209244257
7.34328000853645
Yakoub‑Agha4022801083356494132170209232274312350382
I,79928010831427
Chabannon84128010833977109149182220258296334
C,119128010833952
Bader125828010833467106141162
P1436280108334
et148528010833356
al.15562801083314659
Management163028010835486124157196230288323362383
of34329010833757
adults41529010833272109124147174
and60529010833270109
children7302901083327085100139160194232
undergoing97829010833876115149171209247262300339
chimeric13332901083327085142177199214246
antigen15952901083327092107146181219
recep‑18292901083225688122161185
tor3433001083225879
T‑cell4383001083294881114130145
therapy:5983001083195791112145184215228
best8413001083367198121
practice9773001083365790122145161192226
recommendations12183001083185184120178236270308347379400415453491517
of175030010833554
the18193001083195791
Eu‑19263001083306688
ropean3433101083205796131162199
society5573101083236193108142163196
for7683101083165374
blood8573101083355188126165
and103731010832966105
marrow115631010835586107128165215
transplantation13863101083193972109135173189220257278311332347384422
(EBMT)18233101083154882136169191
and34332010833269108
the4653201083195792
Joint5723201083215974111132
accreditation7193201083296191112146185200222254275290328366
committee110032010832865122179194216240273308
of142332010833554
ISCT14923201083124483119
and162632010832966105
EBMT174632010832964119152
(JA‑19133201083164080101
CIE).3433301083405588108119
Haematologica47733010834477111169202223260276314354369401434
2020;92633010833469101136148
105(2):10903301083346599117151169181
297–316.128633010833468101134166197228241
8.34334000853652
Yescarta,4103401083366793126159180204237250
Souhrn67534010833371109147168207
údajů89734010833877109124162
o1074340108337
přípravku,11273401083386075114136169200231269282
verze14243401083326687118152
z1591340108329
22.16353401083346981
6.173234010833447
2020.179434010833569102136148
9.34335000853649
Neelapu40735010834479114130162201239
SS,6613501083316477
Locke75335010833067100130164
FL,9323501083316276
Bartlett10233501083346788113128163186210
NL124835010834375
et133935010833254
al.14093501083304558
Axicabtagene14833501083397288120152192214247286320359394
cilo‑1892350108330456098121
leucel3433601083155087120153169
CAR52736010834385121
T‑cell6643601083355387120136151
therapy8303601083246398119152191222
in106836010831755
refractory1138360108323577698131164188225246280
large14343601083174970109143
B‑cell15933601083386094128143158
lympho‑176736010831749108147185223247
ma.34337010835790103
N461370108345
Engl52137010833371110125
J661370108325
Med70137010835489129
2017;84537010833468100130139
377:100037010833466101111
2531–2544.112637010833469102133166197232267304317
10.3433800085367085
Locke44238010833067100130164
FL,6213801083316275
Ghobadi71238010834180118158191230245
A,97238010833954
Jacobson10413801083225486123163190228266
CA132338010833880
et141938010833254
al.14883801083304558
Long‑term156238010832966105144166189222243302
safe‑18793801083245877111134
ty34339010832255
and41439010833169108
activity5373901083316387103135151173207
of75939010833756
axicabtagene8303901083326379111143183205238277311350385
ciloleucel1230390108330456199115149187219253269
in151439010831452
refractory1581390108320547395128160185221243277
large18733901083144768106141
B‑cell3434001083355892126141156
lymphoma51540010831749107146185223282314
(ZUMA-1):84440010832160103158200221252267279
a1138400108334
single‑arm,11874001083294482121136171194226247306319
multicentre,152140010836097113135150182216254276297331343
pha‑187940010834280112135
se34341010832661
1–24194101083356799
trial.533410108322435991106119
Lancet66841010833164102135168191
Oncol87441010834786118155171
2019;106041010833468100130143
20:12184101083346982
31–42.13154101083346598135167180
11.2141600085366679
Jacobson2235601083306294132171198237275
C,25266010834558
Chavez26006010834583115147182211
JC,2827601083297084
Sehgal29266010833873111151183199
AR31406010834682
et32386010833962
al.3315601083375366
Primary3396601083416177135168189223
analy‑36356010833775107123155177
sis2141701083264168
of22247010834362
Zuma-5:23027010834380138171194228239
A255770108346
phase26197010834483115142177
2281270108339
study2867701083315593133165
of30477010834362
axicabtagene3125701083376985117150190212245285320358394
ciloleucel3534701083375268106122157195228262278
(axi‑cel)214180108319498196118152186201221
in23778010831957
patients2449801083437698113147186207235
with2699801083557093131
relapsed/refractory2845801083255975107146173208247274293327346369402434458495516550
(R/R)3411801083225886122141
indolent3568801083185695133149184222244
non‑Hodgkin21419010833877116139186225265305336353391
lymphoma25489010832053112152192231290323
(iNHL).2887901083243985130163183194
Blood3097901083415796135176
2020;32889010834075109143157
136(Supple‑34609010834071106125158196236276292328352
ment214110010835792130152
1):23081001083354961
40–41.238410010833470108145175185
12.21411100085366883
Jacobson22391101083225486122162188226264
CA,25181101083388094
Westin262711010835588115138153190
JR,28321101083225872
Miklos29191101083526797113151177
DB311211010834278
et320511010833254
al.32741101083294457
Phase334611010833370102128163
1/235241101083325488
prima‑36271101083365873131163185
ry214112010832155
analysis221112010833674106121153180195221
of244712010834161
ZUMA-6:252312010834285140182203241253
Axicabtagene27911201083457893125158197220252291326364399
ciloleucel32061201083355065103119154192224258273
(Axi‑Cel)34941201083236497112135177211227246
in375612010831856
combination214113010833168126165181218251272288325364
with25201301083486486124
atezolizumab26591301083305185114152167182211250307339379
(Atezo)30531301083165778112141178196
for32641301083165475
the33541301083205893
treatment34621301083194074106128186221259280
of375813010833454
patients21411401083397293109143181203231
(Pts)23871401083205680107124
with25271401083526890128
refractory2671140108322567597130163187224245279
diffuse2966140108340557493132158193
large31751401083164870108143
B3333140108337
cell3385140108333678398
lymphoma349814010831749107146185223281314
(DLBCL).21411501083196497133173205224235
Cancer239115010834073111143177198
Res26041501083367198
2020;271715010833468101135148
80(1628801501083347089121152
Suppl):304715010833370109149165184196
Abstract325915010834080107130151184216241
nr351515010833758
CT055.358915010834075109144176188
13.21411600085366984
Oluwole224016010835369107159197213248
OO,2503160108353101113
Bishop26311601083415683121159199
MR,284616010836096110
Gisselbrecht29721601083496491118153169208230264297335357
C3344160108346
et340516010834062
al.34831601083375265
ZUMA-7:356416010834387142184206238248
A2141170108341
phase219717010834079111137172
32385170108335
randomized24351701083225593132171229244273307347
trial2797170108323446092107
of292017010833857
axicabtagene29931701083336480112145184206239278313351386
ciloleucel33941701083324763101117152189221255271
(Axi­36801701083206194110132
‑Cel)21411801083216497113132
versus22891801083306485113150176
standard‑of‑care24811801083244780118157190211249271311330351384417438472
(SOC)29691801083174996137158
therapy31421801083205994115148187218
in337618010831351
patients34421801083377092107142180201229
with36871801083496487125
relapsed/refractory21411901083215570103142168203243269289323342364397429453490512546
diffuse2702190108336527190129155190
large29071901083134667105140
B3062190108334
cell3111190108329637994
lymphoma322019010831345103142181219278310
(R/R35451901083175380117
DLB‑367719010834476112135
CL).21412001083407191101
J2258200108324
Clin22972001083405570108
Oncol242120010834785117154170
2018;260720010833468100131143
36(15_suppl):27652001083346988119149185213251290329345365377
TPS7585.315720010833269102136168203237249
14.21412100085377086
Jacobson22442101083306396133174201241280
CA,254021010834690104
Locke266021010833876109140175
FL,28512101083397085
Miklos295121010836177108125164192
DB315921010835188
et326321010834063
al.33422101083385467
Outcomes342521010835393116147185245281308
of374921010834363
patients21412201083397395111146185208236
(Pts)23932201083246084113130
in253922010832059
ZUMA-9,261422010834388144187209244255
a2885220108337
multicenter,2938220108364102118141157189224263285319341351
open‑label330522010834384120159182199232272308324
study36452201083325594134167
of214123010833857
axicabtagene22142301083376985118151191213247286322360396
ciloleucel26262301083365267106122158196229263279
(Axi‑cel)292023010832466100116138172206222242
in317823010832058
relapsed/refractory32522301083266177109149176212252278298333352375409441466503525560
large21412401083154768106141
B2298240108336
cell2350240108333668297
lymphoma246224010831748107146185223281314
(R/R27912401083205683120
LBCL)292624010833369110141161
for31022401083205779
expanded319624010833667107140178217252291
access35032401083336596130157183
and370224010833371110
commercial214125010833168126183218239270285317332
out‑of‑specification24882501083357395114154173193220259294326341359376408440462477515553
(OOS)305625010831662110143161
product.32332501083365794133171203227240
Blood34882501083334886125164
2020;36672501083326698132145
136(Supplement21412601083346499118149187226265281316374409447469
1):26252601083344961
2–3.270126010833468101113
15.21412700085356781
Reshef22362701083326692129163181
R,243227010833245
Miklos24922701083516594110147173
DB,26802701083427789
Timmerman278427010832945101158192212269301338
JM313627010832175
et322627010833052
al.32922701083294456
ZUMA-11:336327010833477130171191221248256
A3634270108337
pha‑368627010833573104126
se214128010832661
1/222172801083325489
multicenter232128010835593108130146177211249271304326
study26622801083244785124156
of283328010833554
axicabtagene29022801083306177109142181203236275309347382
ciloleucel3300280108329445997113148185217251267
(Axi‑cel)35822801083165790106128161195210230
+2141290108342
utomilumab21982901083376097155170186223281313353
patients25662901083397293109143182203231
with28122901083516789127
refractory2955290108320557496129161185222244278
large32482901083154768107141
B3405290108335
cell3456290108331658196
lympho‑356729010831547105145183221245
ma.214130010835790103
Blood22593001083365190128168
2019;244230010833468100130143
134(Supplement_1):26013001083346499119150188227266282317375410448470507539553565
4084.318130010833570106142155
16.21413100085366984
Neelapu224031010834277112128160199237
SS,24923101083306274
Dickinson25823101083425889119136173199237276
M,287331010835265
Ulrickson2953310108341567793124154183221259
ML322731010835284
et332631010833254
al.33953101083294457
Interim34673101083135072105126142199
Ana‑368131010833977109130
lysis2141320108315477488115
of227132010834160
ZUMA-12:234632010834286140182204234264277
A2638320108345
phase269832010834281113140175
22888320108338
study29413201083305391130162
of311832010834161
axicabtagene31943201083356782114147186209241280315353388
ciloleu‑35983201083355065103119154192214
cel21413301083316581
(Axi‑cel)22373301083226396111133167201216236
as248833010833562
first‑line2565330108320375885108128144159197232
therapy28123301083256398120153192223
in305033010831856
patients31213301083427597112147185207234
(Pts)33713301083215780108125
with35123301083536991130
high­36573301083415694132155
‑risk2141340108321435885114
large22713401083154869107142
B2428340108336
cell2480340108332658196
lymphoma259134010831648106146184222281313
(LBCL).29193401083205187128160179190
Blood31243401083365290129168
2020;330834010833569101136148
136(Supple‑34723401083356599118150187226266282317340
ment214135010835792130152
1):23083501083354961
49.23843501083346778
17.21413600085366775
Neelapu223136010834276111126158197234
SS,24803601083306174
Kharfan‑Dabaja256936010833270102123144177214236282314353385400431
MA,301536010835293107
Oluwole31373601083446096147184200234
OO338636010834491
et349236010833153
al.35603601083294457
A3632360108338
pha‑368536010833573105127
se214137010832763
2,222037010834053
open‑label,228937010834384120159183199233273309326339
multicenter2643370108364103119142158191225265287322343
study30023701083325695135168
evaluating318637010834073107123162195217233272312
the351437010832867103
safety36333701083326686121144179
and214138010833270109
efficacy2265380108332506886118150183216
of249638010833554
axicabtagene25663801083296176108141180202235274309347381
ciloleucel2963380108329445997113148185217251267
in324538010831250
combination331038010832966124163179217249271286324362
with36883801083486386124
either21413901083344972110145166
rituximab2322390108321376097129144202234274
or261139010833859
lenalidomide26863901083155088120135150189227286301340375
in307639010831553
patients31443901083397294109144182204231
with33913901083516689127
refractory3533390108322567597130162186223245279
large21414001083154768106141
B‑cell22984001083365993127142157
lymphoma247140010831648106146184222281313
(ZUMA-14).279940010832059103157199221252283300311
Blood31254001083375391130169
2019;331040010833569101131144
134(Supple‑347040010833565101120152189228268284319342
ment_1):214141010835792130152189221236247
4093.240441010833470105138150
18.3939600085366985
Catlett4040601083397294109144166190
G,42466010834256
Lada43176010833063102135
A.44676010834054
Humanigen45376010834380138170208224262297335
reports4888601083195392131153177205
positive51086010833877103118141156188223
data5346601083376991124
with5485601083496587125
lenzilumab3939701083155088117133148185243276315
in42697010831351
the4336701083205893
ZUMA-1944447010833780135177198229259
CAR‑T47197010833881117139169
phase49037010833776108135170
1508870108333
b513670108335
study5187701083244886125157
in53597010831351
DLBCL54257010834477112153185
and39398010833270109
plans4063801083385486124150
to42298010832057
initiate430180108314526789105137158192
a450980108330
potential4555801083377698132170191207239254
registrational4824801083205494109135158179212234249287326358374
study5213801083254886125157
[online].5385801083185492108123161196213225
202139399010833468101133
[cit.40879010831848638699
2021-10-11].42029010833368100132151181213237268295311323
Dostupné45409010834584110134172211249284
z:48409010832841
https://www.businesswi‑4897901083375983122149162188209260313367377417456482497535570596623675691713
re.com/news/home/20210419005250/en/3939100108321556799136194220257292343370395434473531566592627661694726757793824854890926960993102810621086111811561182
19.39391100085356780
Jacobson40341101083215284120158184221259
CA,43071101083377992
Hunter441411010834177114135168188
B,461711010833244
Armand467611010833858115147184222
P4913110108332
et495911010833153
al.50261101083294456
Axicabtagene50971101083376984115147185207239277311348382
cilo‑5493110108328435795117
leucel39391201083155087119153169
in412312010831250
the41881201083205893
real4296120108318528499
world:441112010834885107123162174
outcomes46001201083357395126163221256283
and489812010833068107
predictors50201201083365892131146178202239261288
of532312010833554
respon‑53921201083195380118157196218
se,39391301083266072
resistance4026130108318517892118140173210242275
and431613010832966104
toxicity.44351301083195685101132147169202212
Blood46621301083324785123162
2018;48391301083316596126138
132(Supplement49921301083316193110141178216255271305362397434455
1):54621301083314557
92.55341301083316476
20.39391400085367287
Jacobson40411401083265991128167194232271
CA,43271401083428499
Hunter444114010834684122143177198
BR,46541401083387488
Redd475714010833772112151
R4923140108337
et497614010833658
al.50491401083344962
Axicabtagene51271401083427591123156195217250289324362397
ci‑55391401083334871
loleucel39391501083155470106144177211227
in418215010832059
the425615010832766102
non‑trial437415010834382121144167189205237253
setting:46431501083326790115131169209221
outcomes488015010834382105136174233269296
and519215010833776116
correlates53241501083367496118153169202224258286
of393916010833757
response,40111601083266087126165204230265278
resistance,43041601083266087102128151184222255289301
and462016010833775114
toxicity.47501601083276494110142157180214224
J4989160108329
Clin50341601083456075113
Oncol516316010835291123160176
2020;535516010833973106140153
38:55241601083397486
3095–3106.393917010833469104138174207238269305318
21.39391800085367082
Nastoupil403618010834578104127164202241257272
LJ,43241801083315870
Jain44101801083245671109
MD,4535180108354100111
Feng466118010833367105144
L4820180108332
et486718010833557
al.49391801083324760
Standard‑of‑care50151801083325486124163196217255277317336357390423444478
axi‑55091801083326379101
cabtagene393919010833164103125158197232270305
ciloleucel42601901083365166104120155193225258274
for45491901083236183
relapsed46471901083266075107147173208248
or491019010834264
refractory49891901083266079101134166190227249283
large52871901083205273111146
B‑cell54491901083406396130146161
lymphoma:393920010831547105144183221279312324
results42782001083235784121136159187
from44802001083204280138
the46332001083246297
US474520010834678
lymphoma483820010831749107147185223282314
CAR516720010834285121
T5303200108335
consorti‑535320010833370108135173195219235257
um.393921010833795108
J4063210108324
Clin41022101083405570108
Oncol422521010834786118155171
2020;441121010833469101135148
38:45752101083346881
3119–3128.46712101083346593123160193224254287301
22.39392200085367288
Vercellino40432201083377091122156171186201239278
L,433622010833246
Di439722010834762
Blasi44742201083375385111126
R,461622010833650
Kanoun468122010833670108146184222
S4919220108333
et496722010833558
al.50402201083334861
Predictive51162201083375791131146178202217250284
factors54162201083195285109146167194
of393923010833858
early40132301083397294110143
progression417123010834567105146168202230257273311351
after45382301083375782117139
CAR469323010834689126
T‑cell48352301083385791126142158
therapy500823010832867103124158198230
in525423010832059
relapsed/53292301083266177110150178214254281
refractory3939240108321557496130162186223245279
diffuse4234240108343587897136162198
large44472401083205274112147
B‑cell46092401083416498132147163
lymphoma.478724010832052111150189227286318332
Blood51342401083415795134174
Adv532324010834685118
2020;545624010833974107141154
4(22):39392501083345488122140152
5607–5615.410625010833569104137169203238268298310
23.39392600085357186
Bethge40402601083326789126164198
WA,425326010835492106
Holtick43742601083417894115130161191
U,458026010834051
Wagner‑Drouet464626010835484123160194215234280301338375409431
EM,50922601083298396
et520326010833153
al.52712601083284356
Standard­53422601083295082119157189209247268
‑of‑care39392701083216180100134167188222
CAR‑T417627010834588124146176
cell43672701083367086101
therapy448327010832765100121154193224
for47232701083236182
large48212701083195273111146
B‑cell49822701083406397131146161
lymphoma:515927010831951110149187226284316329
real55032701083256091107
world393928010835188110126165
data41192801083447698131
Germany.426528010834984106164197235265275
EBMT455628010833873128162
annual473328010833775113151183199
meeting494728010836298133155171209248
2021,521028010834074107138147
abstract537228010833777103127148181213238
AA2–2.393929010834184120154186198
24.39393000085377288
Folber40443001083387693133169191
F.425130010833946
Update431230010835190131164187222
ZUMA-1454930010834489145188211242
(4leté48073001083255975110134168
sledování49913001083324884124164197230270285
)5281300108318
a5315300108338
dlouho‑53693001083446099139178217241
dobé393931010833876116151
zkušenosti41063101083316199126160199237264287302
s4423310108329
léčbou44683101083175284123162200
přípravkem46843101083416378117139172203234268326
Yescarta50253101083386996128161182207240
v5280310108335
ČR533031010834378
a5423310108335
v5473310108335
za‑55233101083316487
hraničí.39393201083386093132148180196209
II.41643201083203649
Český422932010834680108138173
hematologický441832010834379138171193231247286326342374405440
a4873320108338
transfuziologický49273201083274983121148169208238254293309348389404437468502
sjezd,54453201083324782113152165
13.39393301083346477
9.403133010833445
2021,409133010833569101133142
Olomouc.424833010834763101160198236268282
25.39393400085367287
Wang404134010835889127166
M,422234010835568
Munoz430534010835593131169197
J,451734010832436
Goy456934010834382113
A4698340108340
et475434010833456
al.48253401083324760
KTE‑X19490034010833572106127164195225
CAR514134010833982118
T‑cell52743401083335185118134149
thera‑54383401083226095116149172
py393935010833970
in402435010831452
relapsed40913501083205470102141168203242
or434835010833758
refractory4422350108319537295128160184221242276
mantle‑cell471435010835689127148164198222255289305320
lymphoma.504935010831446104143182220278311324
N5388350108344
Engl544735010833270109124
J5587350108323
Med393936010835490129
2020;408336010833569102136148
382:424736010833468102114
1331–1342.43773601083346497128161191221257289302
26.39393700085367187
Shah404137010833169101139
BD,41953701083348090
Bishop43013701083334874112151190
MR,450637010835389103
Oluwole46243701083456199150188204238
OO487837010834593
et498637010833255
al.50563701083304558
End512937010833168107
of525237010833554
phase532237010833675107134169
I5506370108313
re‑55343701083185276
sults39393801083266378100127
of408238010833453
ZUMA-3,415038010833579133175196228240
a4405380108329
phase444938010833674106132167
1/246313801083325388
study47343801083234684123154
of490338010833554
KTE‑X19,497238010833268102123160191221231
anti‑CD1952183801083296788103125168213244274
chi‑55073801083286681103
meric393939010835792113129160
antigen41153901083296788103142177215
receptor43453901083185285118157179216237
(CAR)45983901083165597133152
T4765390108330
cell4810390108329627893
therapy,49183901083195792113146185216226
in515939010831250
adult522439010833068106121143
patients53823901083376991106141179200228
(pts)39394001083185880107124
with40784001083486386123
relapsed/refractory4217400108318516799138164199238264283317336358391422446483504538
(R/R)47704001083165279115134
acute49194001083296198121154
lymphoblastic508840010831344102141179217257272304331354369400
leu‑55034001083134785107
kemia393941010833064122137169
(ALL).41234101083196092124143154
J4292410108324
Clin43324101083395570107
Oncol445541010834785118155170
2019;464141010833468100130143
37(15_suppl):47994101083346683114144180209246285324340360372
7006.518641010833467103139152